133 related articles for article (PubMed ID: 19150015)
1. [Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia].
Oliva J; López-Bastida J; Moreno SG; Mata P; Alonso R
Rev Esp Cardiol; 2009 Jan; 62(1):57-65. PubMed ID: 19150015
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
[TBL] [Abstract][Full Text] [Related]
3. Cascade genetic screening for familial hypercholesterolemia.
Leren TP
Clin Genet; 2004 Dec; 66(6):483-7. PubMed ID: 15521974
[TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study.
Rogowski WH
Med Decis Making; 2009; 29(2):224-38. PubMed ID: 19182214
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening.
Leren TP; Finborud TH; Manshaus TE; Ose L; Berge KE
Community Genet; 2008; 11(1):26-35. PubMed ID: 18196915
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.
Rubió PP
Public Health; 1997 Jan; 111(1):33-40. PubMed ID: 9033222
[TBL] [Abstract][Full Text] [Related]
8. Screening for familial intracranial aneurysms: decision and cost-effectiveness analysis.
Takao H; Nojo T; Ohtomo K
Acad Radiol; 2008 Apr; 15(4):462-71. PubMed ID: 18342771
[TBL] [Abstract][Full Text] [Related]
9. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.
Smith KJ; Monsef BS; Ragni MV
Thromb Haemost; 2008 Sep; 100(3):447-52. PubMed ID: 18766261
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
Chen CX; Hay JW
Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.
Vegter S; Perna A; Hiddema W; Ruggenenti P; Remuzzi G; Navis G; Postma MJ
Pharmacogenet Genomics; 2009 Sep; 19(9):695-703. PubMed ID: 19696696
[TBL] [Abstract][Full Text] [Related]
13. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
16. Will genetic testing alter the management of disease caused by infectious agents? A cost-effectiveness analysis of gene-testing strategies for prevention of rheumatic Fever.
King CH; Fischler DF; Gerkin RD
Clin Infect Dis; 2002 Jun; 34(11):1491-9. PubMed ID: 12015696
[TBL] [Abstract][Full Text] [Related]
17. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.
Wordsworth S; Leal J; Blair E; Legood R; Thomson K; Seller A; Taylor J; Watkins H
Eur Heart J; 2010 Apr; 31(8):926-35. PubMed ID: 20299350
[TBL] [Abstract][Full Text] [Related]
18. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis.
Scheetz MH; Bolon MK; Postelnick M; Noskin GA; Lee TA
J Antimicrob Chemother; 2009 Apr; 63(4):816-25. PubMed ID: 19202150
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
